Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.

By S. H. Naderi, J. Bestwick, D. Wald. American Journal of Medicine, 2012

788 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Family Practice

View Paper: https://www.semanticscholar.org/paper/fbf900ae76bd7711223bd63f4c34caaf4cdd6305

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Rhian M. Touyz
2. Marja-Riitta Taskinen
3. I. Graham
4. Gerhard Hindricks
5. Stephan Windecker

In Family Practice

1. I. Graham

Citations in the corpus

• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “59 Poor adherence rates are not only limited to statins but are also true of other lipid-lowering drugs and all medications used to prevent CVD, as demonstrated in a systematic review and metaanalysis.(60) The reasons for non-adherence are complex and include misconceptions about tolerability on the”
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, methodology): “and all medications used to prevent CVD, as demonstrated in a systematic review and meta-analysis.(462)”
• 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2017, background): “patients, adherence to cardiovascular medications was estimated to be about 57% after a median of 2 years.(319)”